Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL392 Target Snapshot

A549 · CELL-LINE · Homo sapiens

103,253Compounds
18,154Assays
160Approved Drugs
52,116.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats A549 as ChEMBL target CHEMBL392. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
A549
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL392
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether A549 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelA549
UniProt AccessionN/A

A549

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as A549.

Review nameA549
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

160
Approved
59
Phase III
107
Phase II
27
Phase I
Assay Mix

Activity Type Distribution

IC5050,871.0
EC501,245.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL455213 10.89 IC50 0.013 Preclinical
CHEMBL1836551 10.82 IC50 0.015 Preclinical
CHEMBL1836547 10.79 IC50 0.0163 Preclinical
CHEMBL2324626 10.72 IC50 0.019 Preclinical
CHEMBL1836543 10.72 IC50 0.019 Preclinical
CHEMBL4528553 10.7 IC50 0.02 Preclinical
CHEMBL1836542 10.64 IC50 0.0228 Preclinical
CHEMBL1813137 10.59 IC50 0.026 Preclinical
CHEMBL1836546 10.57 IC50 0.0271 Preclinical
CHEMBL1836548 10.54 IC50 0.0289 Preclinical
Distribution

pChEMBL Value Distribution

8758
5.0
5497
5.5
3264
6.0
1918
6.5
1429
7.0
910
7.5
550
8.0
255
8.5
171
9.0
52
9.5
pChEMBL
Approved Drugs

Approved Drugs

TIRBANIBULIN
CHEMBL571546
Approved 2020
SELUMETINIB
CHEMBL1614701
Approved 2020
FEDRATINIB
CHEMBL1287853
Approved 2019
DACOMITINIB ANHYDROUS
CHEMBL2110732
Approved 2018
PLITIDEPSIN
CHEMBL451930
Approved 2018
TIVOZANIB
CHEMBL1289494
Approved 2017
ABEMACICLIB
CHEMBL3301610
Approved 2017
BRIGATINIB
CHEMBL3545311
Approved 2017
OLMUTINIB
CHEMBL3786343
Approved 2016
PALBOCICLIB
CHEMBL189963
Approved 2015
PANOBINOSTAT
CHEMBL483254
Approved 2015
OSIMERTINIB
CHEMBL3353410
Approved 2015
CERITINIB
CHEMBL2403108
Approved 2014
IDELALISIB
CHEMBL2216870
Approved 2014
EMPAGLIFLOZIN
CHEMBL2107830
Approved 2014
BELINOSTAT
CHEMBL408513
Approved 2014
DABRAFENIB
CHEMBL2028663
Approved 2013
TRAMETINIB
CHEMBL2103875
Approved 2013
AFATINIB
CHEMBL1173655
Approved 2013
CABOZANTINIB
CHEMBL2105717
Approved 2012
TOFACITINIB
CHEMBL221959
Approved 2012
CRIZOTINIB
CHEMBL601719
Approved 2011
CABAZITAXEL
CHEMBL1201748
Approved 2010
ROMIDEPSIN
CHEMBL343448
Approved 2009
CARFILZOMIB
CHEMBL451887
Approved 2009
OMACETAXINE MEPESUCCINATE
CHEMBL46286
Approved 2009
VINFLUNINE
CHEMBL2110725
Approved 2009
TEMSIROLIMUS
CHEMBL1201182
Approved 2007
VORINOSTAT
CHEMBL98
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
ERLOTINIB
CHEMBL553
Approved 2004
PEMETREXED
CHEMBL225072
Approved 2004
MYCOPHENOLIC ACID
CHEMBL866
Approved 2004
GEFITINIB
CHEMBL939
Approved 2003
TEMOPORFIN
CHEMBL500576
Approved 2001
EPIRUBICIN
CHEMBL417
Approved 1999
RALTITREXED
CHEMBL225071
Approved 1996
GEMCITABINE
CHEMBL888
Approved 1996
TOPOTECAN
CHEMBL84
Approved 1996
IRINOTECAN
CHEMBL481
Approved 1996
DOCETAXEL ANHYDROUS
CHEMBL92
Approved 1995
DOCETAXEL
CHEMBL3545252
Approved 1995
MYCOPHENOLATE MOFETIL
CHEMBL1456
Approved 1995
VINORELBINE TARTRATE
CHEMBL538943
Approved 1994
VINORELBINE
CHEMBL553025
Approved 1994
TRIMETREXATE
CHEMBL119
Approved 1993
TENIPOSIDE
CHEMBL452231
Approved 1992
PACLITAXEL
CHEMBL428647
Approved 1992
PODOFILOX
CHEMBL61
Approved 1990
MITOXANTRONE
CHEMBL58
Approved 1987
Source · ChEMBL 36 via Core Engine